Development of dds using hollow bio-nanoparticles and their commercialization

Akihiko Kondo; Shun ichi Kuroda; Katsuyuki Tanizawa; Masaharu Seno; Masakazu Ueda

doi:10.2745/dds.21.435

Development of dds using hollow bio-nanoparticles and their commercialization

Akihiko Kondo, Shun ichi Kuroda, Katsuyuki Tanizawa, Masaharu Seno, Masakazu Ueda

Research output: Contribution to journal › Article › peer-review

Abstract

We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

Original language	English
Pages (from-to)	435-443
Number of pages	9
Journal	Drug Delivery System
Volume	21
Issue number	4
DOIs	https://doi.org/10.2745/dds.21.435
Publication status	Published - 2006

Keywords

gene therapy
hepatitis B virus
nanoparticle
pinpoint drug delivery
targeting

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2745/dds.21.435

Cite this

@article{4de0888085364d4ea10c1d006307ba9d,

title = "Development of dds using hollow bio-nanoparticles and their commercialization",

abstract = "We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.",

keywords = "gene therapy, hepatitis B virus, nanoparticle, pinpoint drug delivery, targeting",

author = "Akihiko Kondo and Kuroda, {Shun ichi} and Katsuyuki Tanizawa and Masaharu Seno and Masakazu Ueda",

year = "2006",

doi = "10.2745/dds.21.435",

language = "English",

volume = "21",

pages = "435--443",

journal = "Drug Delivery System",

issn = "0913-5006",

publisher = "Japan Society of Drug Delivery System",

number = "4",

}

TY - JOUR

T1 - Development of dds using hollow bio-nanoparticles and their commercialization

AU - Kondo, Akihiko

AU - Kuroda, Shun ichi

AU - Tanizawa, Katsuyuki

AU - Seno, Masaharu

AU - Ueda, Masakazu

PY - 2006

Y1 - 2006

N2 - We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

AB - We succeeded overproduction of the HBV envelope L particles with an approximate average particle size of 80 nm in yeast cells. Because the L particle is an empty bionanoparticles containing no viral DNA, it can be used as a safe and efficient carrier for human liver-specific delivery (pinpoint delivery) of drug and gene. In addition, genetically engineered L particles that are able to target to various organs were constructed by deleting the hepatocyte binding domain of L protein (pre-S region) and displaying targeting peptide or protein ligands. Therefore, bionanoparticles are a novel nano-carrier applicable to the broad range of pinpoint DDS.

KW - gene therapy

KW - hepatitis B virus

KW - nanoparticle

KW - pinpoint drug delivery

KW - targeting

UR - http://www.scopus.com/inward/record.url?scp=85024471530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024471530&partnerID=8YFLogxK

U2 - 10.2745/dds.21.435

DO - 10.2745/dds.21.435

M3 - Article

AN - SCOPUS:85024471530

SN - 0913-5006

VL - 21

SP - 435

EP - 443

JO - Drug Delivery System

JF - Drug Delivery System

IS - 4

ER -

Development of dds using hollow bio-nanoparticles and their commercialization

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this